Comparative Pharmacology
Head-to-head clinical analysis: OMNIPAQUE 140 versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OMNIPAQUE 140 versus VASCORAY.
OMNIPAQUE 140 vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Radiopaque contrast agent that attenuates X-rays due to iodine content, enhancing vascular and tissue visualization.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
Intravascular: 50-200 mL (containing 7.0-28.0 g iodine) per procedure, administered intravenously as a bolus or infusion; dose depends on imaging modality and body region. Intrathecal: 6-15 mL (containing 0.84-2.1 g iodine) administered via lumbar puncture for myelography.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life: 1–2 hours; prolonged in renal impairment (up to 30–40 hours in severe dysfunction).
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Renal: >95% unchanged via glomerular filtration; biliary/fecal: negligible (<1%).
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent